ATE402153T1 - Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten - Google Patents

Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten

Info

Publication number
ATE402153T1
ATE402153T1 AT03757914T AT03757914T ATE402153T1 AT E402153 T1 ATE402153 T1 AT E402153T1 AT 03757914 T AT03757914 T AT 03757914T AT 03757914 T AT03757914 T AT 03757914T AT E402153 T1 ATE402153 T1 AT E402153T1
Authority
AT
Austria
Prior art keywords
oxazolylarylpropionic
chiral
acid derivatives
ppar agonists
ppar
Prior art date
Application number
AT03757914T
Other languages
English (en)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Georges Hirth
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE402153T1 publication Critical patent/ATE402153T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03757914T 2002-10-07 2003-10-06 Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten ATE402153T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022286 2002-10-07

Publications (1)

Publication Number Publication Date
ATE402153T1 true ATE402153T1 (de) 2008-08-15

Family

ID=32049977

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03757914T ATE402153T1 (de) 2002-10-07 2003-10-06 Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten

Country Status (31)

Country Link
US (2) US6969725B2 (de)
EP (1) EP1551814B1 (de)
JP (1) JP4414886B2 (de)
KR (1) KR100623819B1 (de)
CN (1) CN100415727C (de)
AR (1) AR041481A1 (de)
AT (1) ATE402153T1 (de)
AU (1) AU2003273949B2 (de)
BR (1) BR0315114A (de)
CA (1) CA2499721C (de)
CO (1) CO5540385A2 (de)
DE (1) DE60322408D1 (de)
DK (1) DK1551814T3 (de)
ES (1) ES2311110T3 (de)
GT (1) GT200300218A (de)
HR (1) HRP20050308A2 (de)
IL (1) IL167250A (de)
MX (1) MXPA05003392A (de)
MY (1) MY143576A (de)
NO (1) NO330171B1 (de)
NZ (1) NZ538465A (de)
PA (1) PA8584501A1 (de)
PE (1) PE20040591A1 (de)
PL (1) PL208743B1 (de)
PT (1) PT1551814E (de)
RU (1) RU2303593C2 (de)
SI (1) SI1551814T1 (de)
TW (1) TWI343915B (de)
UY (1) UY28006A1 (de)
WO (1) WO2004031162A1 (de)
ZA (1) ZA200502664B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
EP1569916B1 (de) * 2002-11-15 2009-01-07 Cadila Healthcare Ltd. Substituierte aralkyl verbindungen
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
GB2460784A (en) * 2007-03-07 2009-12-16 Dong A Pharmtech Co Ltd Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
CN101805336B (zh) * 2009-02-13 2012-05-30 天津药物研究院 一类含色氨酸和异恶唑骨架的化合物、其制备方法和用途
US8637096B2 (en) 2009-12-04 2014-01-28 Curtis C. Stojan Compositions and method for enhancing insulin activity
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
WO2013041621A1 (de) 2011-09-20 2013-03-28 Basf Se Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
IL128600A0 (en) * 1996-08-19 2000-01-31 Japan Tobacco Inc Propionic acid derivatives and pharmaceutical compositions containing them
CZ296507B6 (cs) * 1998-03-30 2006-03-15 Japan Tobacco Inc. Zpusob výroby oxazolylethanolových derivátu
MY123337A (en) * 1998-05-11 2006-05-31 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives.
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CZ20013593A3 (cs) * 1999-04-06 2002-03-13 Sankyo Company, Limited Alfa-Substituované deriváty karboxylových kyselin
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
DE10031657A1 (de) 2000-06-29 2002-01-24 Siemens Ag Hochfrequenz-Bauelement
CA2418104A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
ME01310B (me) * 2001-05-15 2011-10-10 Hoffmann La Roche Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists

Also Published As

Publication number Publication date
KR100623819B1 (ko) 2006-09-13
CA2499721C (en) 2011-03-15
UY28006A1 (es) 2004-04-30
TW200409761A (en) 2004-06-16
KR20050055750A (ko) 2005-06-13
JP2006504709A (ja) 2006-02-09
US7348349B2 (en) 2008-03-25
AU2003273949B2 (en) 2007-04-05
IL167250A (en) 2010-12-30
US20040116487A1 (en) 2004-06-17
HK1083339A1 (en) 2006-06-30
CA2499721A1 (en) 2004-04-15
RU2005114373A (ru) 2006-05-10
AU2003273949A1 (en) 2004-04-23
NO330171B1 (no) 2011-02-28
US6969725B2 (en) 2005-11-29
CO5540385A2 (es) 2005-07-29
US20050267180A1 (en) 2005-12-01
MY143576A (en) 2011-05-31
RU2303593C2 (ru) 2007-07-27
PE20040591A1 (es) 2004-08-30
DK1551814T3 (da) 2008-10-27
EP1551814A1 (de) 2005-07-13
PL376363A1 (en) 2005-12-27
ES2311110T3 (es) 2009-02-01
AR041481A1 (es) 2005-05-18
CN100415727C (zh) 2008-09-03
WO2004031162A1 (en) 2004-04-15
ZA200502664B (en) 2006-02-22
MXPA05003392A (es) 2005-06-22
EP1551814B1 (de) 2008-07-23
PT1551814E (pt) 2008-09-22
SI1551814T1 (sl) 2008-10-31
BR0315114A (pt) 2005-08-16
NO20051011L (no) 2005-05-02
DE60322408D1 (de) 2008-09-04
NZ538465A (en) 2007-08-31
PA8584501A1 (es) 2004-05-21
HRP20050308A2 (en) 2006-07-31
TWI343915B (en) 2011-06-21
CN1703406A (zh) 2005-11-30
GT200300218A (es) 2004-05-24
JP4414886B2 (ja) 2010-02-10
PL208743B1 (pl) 2011-06-30

Similar Documents

Publication Publication Date Title
DE60317093D1 (de) Chinolin-; isochinolin- und chinazolinoxyalkylamide und ihre verwendung als fungizide
ATE398108T1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
ATE444068T1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
DE60316012D1 (de) Purinderivate und ihre verwendung als liganden des cannabinoid rezeptors
DE60314600D1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE60317365D1 (de) Substituierte 4-alkoxyoxazol derivate als ppar agonisten
DE60332023D1 (de) Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
ATE442348T1 (de) Amino substituierte phenylessigsäuren sowie deren derivate, deren herstellung und deren verwendung als cyclooxygenase 2 (cox-2) inhibitoren
DE602004028934D1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
ATE399768T1 (de) Indazolderivate und ihre verwendung als crf antagonisten
DE60322408D1 (de) Chirale oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
DE502005007106D1 (de) Substituierte phenylaminothiazole und ihre verwendung
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE362469T1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
ATE382040T1 (de) Acylaminothiazolderivate und ihre vewrendung als beta-amyloid inhibitoren
DE60311598D1 (de) Naphthyridin-derivate und ihre verwendung als fungizide
ATE427748T1 (de) Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
DE60324586D1 (de) Substituierte pyridyloxyalkylamide und ihre verwendung als fungizide
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
ATE368654T1 (de) Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1551814

Country of ref document: EP